MedTrace Logo

Fenofibrate for Patients With COVID-19 Requiring Hospitalization

NCT04661930 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-04-19

No results posted yet for this study

Summary

This is an open-label run-in followed by a randomized, double-blind drug treatment study of COVID-19 infected patients requiring inpatient hospital admission.

Conditions

Interventions

DRUG

TriCor® 145mg tablets

Fenofibrate; 145 mg daily (1/day); oral administration; 10 days

OTHER

Placebo

Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration

OTHER

Usual care

All participants will otherwise receive usual medical care

Sponsors & Collaborators

  • Barzilai Medical Center

    collaborator OTHER

  • Rambam Health Care Campus

    collaborator OTHER

  • Nazareth Hospital

    collaborator OTHER

  • Yaakov Nahmias

    lead OTHER

Principal Investigators

  • Shlomo Mayaan, MD · Barzilai Medical Center

  • Mahram Nassar, MD · Barzilai Medical Center

  • Yaakov Nahmias, PhD · Hebrew University of Jerusalem

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-05-01
Completion
2022-07-01
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04661930 on ClinicalTrials.gov